Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 401-409

  Greathouse, Mark ^a  

^a South Hills Cardiology Associates of Pittsburgh   (United States)

Author keywords

Angiotensin II reeeptor blocker; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE BESYLATE PLUS BENAZEPRIL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS HYDROCHLOROTHIAZIDE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; EPROSARTAN PLUS HYDROCHLOROTHIAZIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; OLMESARTAN; PLACEBO; POTASSIUM; SODIUM; TELMISARTAN; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; MONOTHERAPY; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; VASCULAR RESISTANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME;

EID: 33846931415     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.401     Document Type: Review

References (43)

1. American Heart Association and A. S. Association. 2006. Heart disease and stroke statistics - 2006 update [online]. Accessed 3 March 2006. URL: http://www.americanheart.org
2. Ball KJ, Williams PA, Stumpe KO. 2001. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens, 19(Suppl 1):S49-56.
3. Benz JR, Black HR, Graff A, et al. 1998. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens, 12:861-6.
4. Brown CL, Backhouse CI, Grippat JC, et al. 1990. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol, 39:327-32.
5. Brunner HR, Nussberger J. 2001. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens, 19(Suppl 1):S15-20.
6. Burnier M. 2001. Angiotensin II type 1 receptor blockers. Circulation, 103:904-12.
7. Caro JJ, Speckman JL, Salas M, et al. 1999. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ, 160:41-6.
8. Carter BL, Ernst ME, Cohen JD. 2004. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension, 43:4-9.
9. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
10. Chrysant SG. 1994. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Arch Intern Med, 154:737-43.
11. Chrysant SG, Weber MA, Wang AC, et al. 2004. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens, 17:252-59.
12. Conlin PR, Spence JD, Williams B, et al. 2000. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens, 13:418-26.
13. Dahlof B, Deverenx RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
14. Daiichi Sankyo, Inc. 2005. Benicar HCT Prescribing Information.
15. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertens, 21:1011-53.
16. Izzo JL, Levy D Jr., Black HR. 2000. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 35:1021-4.
17. Kjeldsen SE, Os I, Hoieggen A, et al. 2005. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs, 5:17-22.
18. Kochar M, Guthrie R, Triscari J, et al. 1999. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens, 12:797-805.
19. Koike H, Sada T, Triscuri J, et al. 2001. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens, 19(Suppl):S3-14.
20. Kreutz R, Bolbrinker J, Huber T. 2006. Pharmacokinetics of olmesartan plus hydrochlorothiazide combination in healthy subjects. Clin Drug Invest, 26:29-34.
21. Lacourciere Y, Neutoe JM, Schumacher H. 2005. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther, 27:1795-805.
22. Laeis P, Puchler K, Kirch W. 2001. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens, 19(Suppl):S21-32.
23. Mancia G, Bombelli M, Lanzarotti A, et al. 2002. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorato E Loro Associazioni. Arch Intern Med, 162:582-6,
24. Manolis AJ, Grossman E, Jelakovic B, et al. 2000. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther, 22:1186-203.
25. McGill JB, Reilly PA. 2001. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther, 23:833-50.
26. Meredith PA. 2005. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs, 5:171-83.
27. Mizuno M, Sada T, Ikeda M, et al. 1995. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist Eur J Pharmacol, 285:181-8.
28. Neutel JM. 2001. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol, 87(Suppl):37C-43C.
29. Neutel JM, Saunders E, Bakris GL, et al. 2005. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich), 7:578-86.
30. Neutel JM, Smith DH, Silfani TN, et al. 2006. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension, J Hum Hypertens, 20:255-62.
31. Neutel J, Smith D, Weber MA, et al. 2004. Use of olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich), 6:168-74.
32. Pugsley M. 2006. A characterization of the molecular interactions of olmesartan (OLM) and telmisartan (TEL) with human angiotensin AT1 receptors [abstract]. American Society of Hypertension 21st Annual Scientific Meeting, New York, NY.
33. Quan A, Chavanu K, Merkel J. 2006. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs, 6:103-13.
34. Ram CV. 2004. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich), 6:569-77.
35. Reyes A. 2002. Diuretics in the therapy of hypertension. J Hum Hypertens, 16(Suppl 1):S78-83.
36. Rump LC, Ambrosioni E, Burnier M, et al. 2006. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens, 20:299-301.
37. Sachse A, Verboom CN, Jager B. 2002. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens, 16:169-76.
38. Schwocho LR, Masonson HN. 2001. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol, 41:515-27.
39. Sellin L, Stegbauer J, Laeis P, et al. 2005. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens, 23:2083-92.
40. Singer GM, Izhar M, Black HR. 2002. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension, 40: 464-9.
41. Swales JD. 1999. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J, 138:231-7.
42. Sweetman SC. 2005. Martindale: the complete drug reference. London: Pharmaceutical Press.
43. Whitworth JA. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983-92.